GRAZIA PALOMBA

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8591347/publications.pdf

Version: 2024-02-01

27 papers 526 citations

623574 14 h-index 23 g-index

27 all docs

27 docs citations

27 times ranked

1034 citing authors

#	Article	IF	CITATIONS
1	Long non-coding RNA CASC2 in human cancer. Critical Reviews in Oncology/Hematology, 2017, 111, 31-38.	2.0	54
2	Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Journal of Translational Medicine, 2016, 14, 292.	1.8	43
3	Identification of a founder BRCA2 mutation in Sardinia. British Journal of Cancer, 2000, 82, 553-559.	2.9	42
4	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer, 2009, 9, 352.	1.1	42
5	Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. British Journal of Dermatology, 2007, 158, 071119222739015-???.	1.4	37
6	Breast Nodular Fasciitis: A Comprehensive Review. Breast Care, 2016, 11, 270-274.	0.8	32
7	Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. Journal of Translational Medicine, 2012, 10, 178.	1.8	31
8	Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer, 2005, 104, 1172-1179.	2.0	24
9	KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncology Letters, 2014, 8, 1422-1426.	0.8	21
10	Female Adnexal Tumors of Probable Wolffian Origin (FATWO): A Case Series With Next-Generation Sequencing Mutation Analysis. International Journal of Gynecological Pathology, 2017, 36, 575-581.	0.9	21
11	BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling. Annals of Oncology, 2002, 13, 1899-1907.	0.6	20
12	A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population. BMC Cancer, 2009, 9, 245.	1.1	18
13	Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer, 2009, 9, 62.	1.1	16
14	Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncology Letters, 2014, 7, 948-952.	0.8	16
15	Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. BMC Cancer, 2007, 7, 132.	1.1	15
16	A novel spontaneous missense mutation in VMD2 gene is a cause of a Best macular dystrophy sporadic case. American Journal of Ophthalmology, 2000, 129, 260-262.	1.7	14
17	Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Molecular Medicine Reports, 2015, 12, 187-191.	1.1	14
18	Genome-wide association study of susceptibility loci for breast cancer in Sardinian population. BMC Cancer, 2015, 15, 383.	1.1	12

#	Article	lF	CITATIONS
19	Molecular alterations in key-regulator genes among patients with T4 breast carcinoma. BMC Cancer, 2010, 10, 458.	1.1	11
20	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel. Frontiers in Oncology, 2020, 10, 236.	1.3	11
21	Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. BMC Dermatology, 2009, 9, 7.	2.1	8
22	ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. Journal of Translational Medicine, 2014, 12, 272.	1.8	8
23	Primary Dermal Melanoma in a Patient with a History of Multiple Malignancies: A Case Report with Molecular Characterization. Case Reports in Dermatology, 2013, 5, 192-197.	0.3	7
24	Identification of predictive factors for the occurrence of predisposing MLH1 and MSH2 germline mutations among Sardinian patients with colorectal carcinoma. European Journal of Cancer, 2005, 41, 1058-1064.	1.3	4
25	Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. Oncology Letters, 2016, 12, 1415-1421.	0.8	3
26	KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors. European Journal of Cancer Prevention, 2021, 30, 53-58.	0.6	2
27	Disease progression and overall survival in sardinian patients with colorectal cancer according to the kras mutational status. Annals of Oncology, 2015, 26, vi45.	0.6	O